Weight Loss Medication With No Wait List: Get Started in Days, Not Months
Tired of waiting months to see a specialist or get a GLP-1 prescription? This guide explains how to get semaglutide or tirzepatide within days through telehealth — no wait list, no prior authorization, starting at $99/month.
Written by Trimi Medical Team. Medically reviewed by Trimi Medical Review Board. This article is for informational purposes only.
More on Access & Supply
If you have tried to get a GLP-1 medication through the traditional healthcare system, you have likely encountered multiple friction points: a months-long wait for an obesity medicine specialist, a prior authorization process that takes weeks, a denial that takes more weeks to appeal, and a pharmacy fulfillment queue for brand-name medications.
For patients who are clinically ready to start treatment, that delay has real health consequences. GLP-1 medications produce their greatest clinical benefit during continued use — every month of waiting is a month without treatment.
This guide explains why wait lists exist, which pathways bypass them entirely, and how to get started with GLP-1 treatment in days rather than months.
Why Getting GLP-1 Medications Takes So Long
There are three distinct types of delay in the traditional GLP-1 prescribing pathway — and each has a different cause.
Delay 1: Specialist appointment wait lists (3–6 months)
Obesity medicine specialists have been overwhelmed with demand since GLP-1 medications became widely publicized in 2022–2023. In most metropolitan areas, new patient wait times are 3–6 months. In rural areas, there may be no local obesity medicine specialist at all. Primary care providers can prescribe GLP-1s, but many are hesitant due to insurance complexity, prior authorization burden, or lack of familiarity with the medications.
Delay 2: Prior authorization process (4–12 weeks)
Even after you get the prescription, insurance prior authorization for brand-name GLP-1 medications typically takes 4–8 weeks for a standard review. If the first PA is denied, an appeal adds another 4–8 weeks. By the time the insurance system approves treatment, months have elapsed from your initial request.
Delay 3: Supply shortages (variable, 2022–2024)
Brand-name Wegovy and Ozempic experienced significant supply shortages between 2022 and 2024 driven by unexpected demand growth. Even patients with approved prior authorizations sometimes waited weeks to fill their prescriptions. As of 2026, supply has largely normalized for brand-name, but historical shortages have left many patients cautious about relying solely on brand-name availability.
How Telehealth Bypasses All Three Delays
Telehealth providers like Trimi were built specifically to remove these access barriers. Here is how each delay is eliminated:
No specialist wait list: async evaluation in 24 hours
Instead of booking an appointment months out, you complete an online health assessment that a board-certified provider reviews within 24 hours. No scheduling, no waiting room, no geographic constraint.
No prior authorization: cash-pay direct model
Compounded semaglutide at $99/month is a direct-pay program. There is no insurance billing, no prior authorization, and no PA denial to appeal. The provider approves treatment clinically — that is the only hurdle.
No supply shortage: compounding pharmacy model
Compounding pharmacies produce medication based on prescription demand rather than centralized commercial manufacturing. Trimi's pharmacy network maintains consistent availability and provides advance notice of any supply changes.
The Full Timeline: Traditional vs. Trimi
| Stage | Traditional path | Trimi telehealth |
|---|---|---|
| Get evaluation | Schedule and wait 2–8 weeks (PCP) or 3–6 months (specialist) | Complete online assessment same day — no scheduling |
| Provider decision | At appointment — then submit PA to insurer | Within 24 hours — no PA required |
| Insurance approval | 4–8 weeks (if approved first time) or 8–16 weeks (with appeal) | N/A — direct-pay, no insurance |
| Pharmacy fulfillment | Same day to 1 week (if in stock) | 2–3 business days from approval |
| Delivery | In-person pickup | 3–5 business days shipped to door |
| Total time to first injection | 6–20+ weeks | 7–10 business days |
What "Getting Started in Days" Actually Looks Like
Here is a realistic account of the first two weeks on the Trimi program:
Day 1: Online assessment
You complete the 10-minute health assessment covering your medical history, medications, weight, and goals. This is submitted to the provider queue immediately.
Day 1–2: Provider review
A board-certified provider reviews your assessment. If clinically appropriate, they approve the prescription. If they have questions, they message you — typically resolved same day.
Day 2–5: Pharmacy preparation
Your prescription is prepared at the accredited compounding pharmacy. Batch quality testing is conducted. Your package is assembled with medication, syringes, alcohol wipes, dose schedule, and instructions.
Day 5–10: Delivery
Your package arrives via insulated shipping. Semaglutide is refrigerated on arrival. You administer your first 0.25mg subcutaneous injection that evening.
Week 2: Treatment begins
You have your first weekly injection administered. Appetite suppression effects typically begin within the first 1–2 injections at the starting dose. You message your provider if you have questions.
Why Starting Sooner Matters Clinically
GLP-1 medications produce their greatest clinical benefit during active treatment, and that benefit requires sustained use over months. The STEP-1 trial showed most of the 14.9% average weight loss occurred over a 68-week treatment period — but meaningful appetite suppression and initial weight loss typically begin within the first 4–8 weeks.
Every month of delay is a month without those benefits. For patients with obesity-related comorbidities — type 2 diabetes, hypertension, sleep apnea — the delay in treatment has compounding downstream health costs.
This is not a marketing argument. It is the clinical reality that drove the design of the Trimi program: removing barriers to starting treatment so patients can begin the work of improving their health on their own timeline.
Semaglutide vs. Tirzepatide: Which to Start?
Trimi offers two GLP-1 options, and patients often ask which to choose when starting immediately:
| Factor | Compounded Semaglutide | Compounded Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Average weight loss in trials | ~14.9% (STEP 1) | ~20.9% at highest dose (SURMOUNT-1) |
| Monthly price (Trimi) | $99/month | $125/month |
| Side effect profile | Nausea, GI effects during escalation | Similar GI effects; generally well-tolerated |
| Who tends to choose this | First-time GLP-1 users; cost-sensitive patients | Patients wanting maximum efficacy; prior semaglutide non-responders |
Both options are available immediately — no wait list for either. Most patients starting for the first time begin with semaglutide due to the longer clinical track record and slightly lower monthly cost.
Getting Started: The Exact Steps
- 1Go to trytrimi.com and create an account — takes 2 minutes
- 2Complete the online health assessment — covers medical history, medications, weight, and goals — approximately 10 minutes
- 3A board-certified provider reviews your assessment within 24 hours and makes a prescribing decision
- 4If approved, your prescription is sent to the accredited compounding pharmacy
- 5Medication ships within 2–3 business days via insulated cold-pack delivery
- 6Your first injection arrives in 5–7 business days from signup
- 7Monthly refills at $99/month (semaglutide) or $125/month (tirzepatide)
For more detail on the online evaluation process: GLP-1 without a doctor appointment — how online prescriptions work in 2026.
Can I Start Now and Switch to Insurance Later?
Yes, and this is a common strategy. Many patients start compounded semaglutide through Trimi immediately and simultaneously:
- File an insurance appeal for previously denied brand-name Wegovy coverage
- Wait on a specialist appointment that may eventually lead to brand-name coverage
- Work with their employer to add GLP-1 coverage during the next benefits open enrollment period
If brand-name insurance coverage eventually becomes available, transitioning from compounded semaglutide is straightforward — the molecule is the same, so there is no restart or tapering required. You simply switch to the brand-name prescription at your current dose.
See insurance denied Wegovy — what to do next for the full strategy guide.
Frequently Asked Questions
Why is there a wait list for GLP-1 weight loss medications?
Wait lists for GLP-1 medications exist for two distinct reasons: appointment access delays (obesity medicine specialists often have 3–6 month wait lists in many cities) and supply/pharmacy delays (Wegovy and Ozempic experienced significant shortages from 2022 through 2024 that created fulfillment delays even after approval). In 2026, supply has largely normalized for brand-name drugs, but appointment wait times at specialists remain long. Compounded GLP-1 medications through telehealth providers like Trimi bypass both issues.
How quickly can I start semaglutide through a telehealth provider?
Through Trimi, the typical timeline from account creation to first injection is 7–10 business days: same-day online health assessment, provider review within 24 hours, pharmacy preparation 2–3 business days, delivery 3–5 business days. There is no appointment wait, no specialist referral, and no prior authorization delay.
Is there a supply shortage for compounded semaglutide in 2026?
Compounded semaglutide supply has been more stable than brand-name supply. Compounding pharmacies produce on a per-prescription or planned-batch basis rather than through centralized commercial manufacturing, so they are less subject to the single-point supply failures that affected Novo Nordisk's Wegovy manufacturing. Trimi's pharmacy network maintains stock availability and notifies patients promptly if any disruption occurs.
Can I start immediately if my BMI is exactly at the threshold?
The standard clinical criteria for GLP-1 treatment are BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, sleep apnea, high cholesterol, or cardiovascular disease). If your BMI is at or above these thresholds and you meet the other clinical criteria, you are eligible to start as soon as your provider approves your assessment — there is no minimum waiting period.
What do I do if I can't get an appointment with an obesity specialist?
Obesity medicine specialists in most metropolitan areas have wait lists of 3–6 months. If you cannot access one quickly, telehealth providers like Trimi offer board-certified provider evaluation and compounded GLP-1 prescribing online, typically within 24 hours. This is not a lesser option — it is a different access model designed specifically for patients who cannot navigate the specialist wait-list system.
Can I start Trimi while on a wait list for a specialist?
Yes. Starting compounded semaglutide through Trimi while you wait for a specialist appointment is a common and practical approach. You begin treatment and see clinical results while waiting. When your specialist appointment arrives, you can discuss transitioning to brand-name coverage if that is your preference, or continue with the compounded program.
Is there a limit to how long I can stay on the Trimi program?
There is no time limit on the Trimi program. GLP-1 medications are intended for long-term use — STEP 4 trial data showed that patients who stopped semaglutide regained most of the weight they had lost. Trimi supports ongoing monthly treatment at $99/month for semaglutide or $125/month for tirzepatide for as long as treatment is clinically appropriate.
Related Reading
Sources & References
- STEP 1 trial: Wilding JPH et al. Once-Weekly Semaglutide. NEJM 2021;384:989–1002.
- SURMOUNT-1 trial: Jastreboff AM et al. Tirzepatide for Obesity. NEJM 2022;387:205–216.
- STEP 4 trial: Rubino D et al. Continued semaglutide vs. withdrawal. JAMA 2021;325:1414–1425.
- FDA Drug Shortage Database — historical semaglutide shortage information.
- FDA guidance on pharmaceutical compounding.
Medical Disclaimer: This content is for informational purposes only. Timelines and availability described are typical as of April 2026 and subject to change. Consult a licensed healthcare provider before starting any medication program.